Michael Andreeff, M.D., Ph.D to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc.
May 21 2021 - 7:30AM
Business Wire
Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX)
("Brooklyn"), a biopharmaceutical company focused on exploring the
role that cytokine and gene editing/cell therapy can have in
treating patients with cancer and blood disorders, today announced
the appointment of Michael Andreeff, M.D., Ph.D. to Brooklyn’s
Scientific Advisory Board, effective May 21, 2021.
Dr. Andreeff currently serves as a Professor of Medicine at MD
Anderson Cancer Center where he holds the Paul and Mary Haas Chair
in Genetics and is the Chief of Molecular Hematology and Therapy.
Dr. Andreeff received his M.D. and Ph.D. from the University of
Heidelberg, Germany, and additional training at Memorial Sloan
Kettering Cancer Center (MSKCC). Dr. Andreff has been a pioneer in
flow cytometry since 1971, when he established the first flow
cytometry laboratory at the University of Heidelberg and organized
the first European flow cytometry conference. In 1977 he joined
MSKCC, became head of the Leukemia Cell Biology and Hematopathology
flow cytometry laboratory, and organized the first Clinical
Cytometry Conference in 1986. Since 1990 he has been Professor of
Medicine at MD Anderson Cancer Center. He has published over 700
peer-reviewed papers, 5 books and 75 book chapters.
“Dr. Andreeff brings a tremendous amount of experience in
developing treatments for leukemia and I am thrilled to welcome him
to Brooklyn’s Scientific Advisory Board,” said Howard J. Federoff,
M.D., Ph.D., Chief Executive Officer and President of Brooklyn. “He
is an established leader in analyzing the interactions between
leukemia stem cells and their microenvironment. He has also laid
the foundation for using mesenchymal stem cells in cancer therapy.
Dr. Andreeff’s expertise will be crucial as we continue to advance
our work in the gene editing and cell therapy space.”
“Having worked extensively in the leukemia space, I am eager to
join the Brooklyn team and contribute to their efforts to develop
impactful oncology therapies,” said Dr. Andreeff. “With the recent
license with Factor Bioscience Limited and Novellus Therapeutics
Limited’s gene editing technology, Brooklyn has tremendous
potential as a leader in cancer therapy with a diverse pipeline of
products. I am excited to be a part of this team.”
About Brooklyn ImmunoTherapeutics
Brooklyn is exploring the role that cytokine-based therapy can
have in treating patients with cancer, both as a single agent and
in combination with other anti-cancer therapies. The company is
also exploring opportunities to advance oncology, blood disorder,
and monogenic disease therapies using leading edge gene
editing/cell therapy technology through the newly acquired license
from Factor Bioscience and Novellus Therapeutics.
Brooklyn’s most advanced program is studying the safety and
efficacy of IRX-2 in patients with head and neck cancer. In a Phase
2A clinical trial in head and neck cancer, IRX-2 demonstrated an
overall survival benefit. Additional studies are either underway or
planned in other solid tumor cancer indications.
For more information about Brooklyn and its clinical programs,
please visit www.BrooklynITx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210521005081/en/
Media MacDougall Nicholas Chang 781-235-3060
nchang@macbiocom.com
IR CORE IR 516-222-2560 investors@brooklynitx.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Jul 2023 to Jul 2024